Article | May 3, 2017

The Role of Biomarkers, Companion and Complementary Diagnostics

Source: Covance

By Steven M. Anderson, PhD, Chief Scientific Officer, Covance

immuno-oncology diagnostics

The recent evolution of immunotherapies and their potential applications have greatly impacted patients’ options for effective oncology treatments. These advances have been powered in part by the use of biomarkers, companion diagnostics (CDx) and complementary diagnostics.